Forbes.com: Markets News - 13:29 ET Mar 18, 2010Teva Pharmaceutical Industries Ltd. (TEVA)
-
Glen Santangelo
at
Credit SuisseAccording to Credit Suisse analyst Glen Santangelo, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%. Adding opportunity for generic drugmakers like
Teva, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of
Teva traded on the Nasdaq exchange gained $1.82, or 3%, to $61.76 Thursday
Share:
<span class="sent">According to Credit Suisse analyst <span class="analyst">Glen Santangelo</span>, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%.</span> Adding opportunity for generic drugmakers like <span class="company">Teva</span>, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of <span class="company">Teva</span> traded on the Nasdaq exchange gained $1.82, or 3%, to $61.76 Thursday....<span class="sent">According to Credit Suisse analyst <span class="analyst">Glen Santangelo</span>, February monthly generic prescription volume ticked up 2.8% year over year, while branded prescription volume dipped 10.1%.</span> Adding opportunity for generic drugmakers like <span class="company">Teva</span>, the analyst says he expects generic utilization to climb as high as 82% by 2015, up from the current dispensing rate of 69%. American depositary receipts of <span class="company">Teva</span> traded on the Nasdaq exchange gained $1.82, or 3%, to $61.76 Thursday.
Tweet this